NR4A1 and breast cancer: BACKGROUND: Abemaciclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, is standard adjuvant therapy for hormone receptor (HR)-positive, HER2-negative early breast cancer.